ArticleInternational journal of cardiology. Cardiovascular risk and prevention2026
Oxidative balance score as a predictor of MASLD-CVD comorbidity risk and mortality: Insights from traditional and machine learning approaches.
Article in International journal of cardiology. Cardiovascular risk and prevention, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Oxidative stress underlies both metabolic dysfunction-associated steatotic liver disease (MASLD) and cardiovascular disease (CVD). The oxidative balance score (OBS) quantifies systemic oxidative stress from pro-/antioxidant exposures, but its role in MASLD-CVD comorbidity is unknown. Methods: We analyzed 19,993 adults from NHANES 1999-2018. Multinomial logistic and Cox regression assessed OBS associations with comorbidity risk and all-cause mortality. Machine learning and SHAP interpretability analysis identified key predictors, and bioinformatics explored mechanistic pathways. Results: Lower OBS quartiles were associated with higher odds of prevalent MASLD (Q1 OR = 1.31), CVD (Q1 OR = 1.95), and MASLD-CVD comorbidity (Q1 OR = 2.15). Each unit increase in OBS reduced mortality risk (MASLD-CVD: HR = 0.98; MASLD: HR = 0.98; CVD: HR = 0.99). Critical OBS thresholds were identified: OBS<8.73 increased mortality risk in MASLD patients (HR = 1.09), while OBS≥8.73 was protective (HR = 0.96). For MASLD-CVD, OBS = 21 optimally stratified mortality risk (log-rank P = 0.0018). SHAP analysis revealed the nonlinear contributions of key dietary/lifestyle factors. The key pro-oxidant factors may contribute to comorbidity development through IL-17 and insulin resistance pathways, as suggested by bioinformatics analysis. Conclusions: OBS enables risk stratification for MASLD-CVD comorbidity, but external validation is required before clinical application.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.